Reports Q4 revenue $20.54M, consensus $20.32M. "We drove strong adoption and increased utilization of all our products to generate substantial revenue growth in 2022," said Paul Badawi, co-founder and Chief Executive Officer of Sight Sciences. "Our improved fourth quarter 2022 financial results reflected the impact of the operating expense rationalization initiative we began in the third quarter. In 2023, we plan to generate sustainable growth while continuing to improve operating efficiency and maintain strict financial discipline. This will allow us to further exploit the operating leverage we flexed in the fourth quarter."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on SGHT:
- Sight Sciences Reports Fourth Quarter and Full Year 2022 Financial Results
- Sight Sciences launches Ergo-Series of OMNI Surgical System
- Sight Sciences Launches the Ergo-Series of the OMNI® Surgical System
- Sight Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023
- Sight Sciences announces 1,000th TearCare customer installation